Results of AGM

RNS Number : 9082E

ConvaTec Group PLC

11 May 2017

 

Result of Meeting

CONVATEC GROUP PLC - AGM

11 MAY 2017 - POLL RESULT

ConvaTec Group Plc ("ConvaTec"), a leading global medical products and technologies company, held its annual general meeting today.  The results of the poll held in relation to the resolutions proposed at the meeting are set out below.

		For (see note 2)		Against (see note 2)		Number of votes Withheld (see note 3)	Total Capital Instructed
Resolution		No of shares	%	No of Shares	%
1	Receive Annual Reports and Accounts	1,673,547,389	99.40	10,098,465	0.60	687,156	86.28%
2	Approve the Directors' Remuneration Report	1,649,328,475	97.94	34,666,528	2.06	338,007	86.29%
3	Approve the Directors' Remuneration Policy	1,674,663,195	99.45	9,331,808	0.55	338,007	86.29%
4	Elect Sir Christopher Gent as a director	1,676,668,959	99.58	7,122,017	0.42	542,034	86.28%
5	Elect Paul Moraviec as a director	1,659,821,604	98.56	24,175,399	1.44	336,007	86.29%
6	Elect Nigel Clerkin as a director	1,659,401,604	98.54	24,595,399	1.46	336,007	86.29%
7	Elect Steve Holliday as a director	1,677,375,498	99.61	6,621,505	0.39	336,007	86.29%
8	Elect Jesper Ovesen as a director	1,671,684,756	99.27	12,312,247	0.73	336,007	86.29%
9	Elect Rick Anderson as a director	1,679,301,346	99.72	4,695,657	0.28	336,007	86.29%
10	Elect Raj Shah as a director	1,646,289,348	98.06	32,613,689	1.94	5,429,973	86.03%
11	Elect Kasim Kutay as a director	1,655,528,107	98.31	28,468,896	1.69	336,007	86.29%
12	Appoint Deloitte LLP as auditors	1,683,082,895	99.95	914,108	0.05	336,007	86.29%
13	Authorise the Directors to agree the auditors' remuneration	1,681,391,151	99.85	2,605,452	0.15	336,407	86.29%
14	Authorise allotment of shares	1,529,102,605	90.93	152,583,558	9.07	2,646,847	86.18%
15	Authorise scrip dividend alternative	1,683,571,466	99.97	425,537	0.03	336,007	86.29%
16	Disapply pre-emption rights*	1,680,232,470	99.76	4,052,383	0.24	48,157	86.31%
17	Disapply pre-emption rights in connection with an acquisition or specified capital investment*	1,505,385,444	89.38	178,899,409	10.62	48,157	86.31%
18	Authorise purchase of own shares*	1,679,583,213	99.82	3,010,097	0.18	1,739,700	86.22%
19	Approve SAYE option scheme	1,680,350,606	99.77	3,932,247	0.23	50,157	86.31%
20	Approve US Employee Share Purchase Plan	1,683,935,777	99.98	347,076	0.02	50,157	86.31%
21	Authorise political donations and political expenditure	1,682,860,783	99.93	1,136,220	0.07	336,007	86.29%
22	Call general meetings on 14 days' notice*	1,662,315,089	98.71	21,681,914	1.29	336,007	86.29%

*Special Resolution

NOTES:

1.   All resolutions were passed.

2.   Votes "For" and "Against" are expressed as a percentage of votes received.

3.   A "Vote withheld" is not a vote in law and is not counted in the calculation of the votes "For" or "Against" a resolution.

4.   Total number of shares in issue at 6.30pm on 9 May 2017 was 1,951,472,651 shares.  XX.XX% of voting capital was instructed.

About ConvaTec

ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions. The Company is listed on the London Stock Exchange (stock symbol: CTEC) and has leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion devices. ConvaTec's products provide a range of clinical and economic benefits, including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care.  www.convatecgroup.com

This information is provided by RNS

The company news service from the London Stock Exchange

Enquiries

Analysts and Investors

John Crosse, VP Investor Relations, ConvaTec                             [phone]

Kirsty Law, Director Investor Relations, ConvaTec                         [phone]

[e-mail]

Media

Bobby Leach, VP Group Corporate Affairs, ConvaTec                    [phone]

Rebecca Fitchett, Finsbury                                                         [phone]

# # #

END

 

END

 

 

RAGOKDDBNBKDDPD